Q3 2024 13F Holders as of 30 Sep 2024
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
74,361,296
-
Number of holders
-
61
-
Total 13F shares, excl. options
-
30,026,264
-
Shares change
-
+2,389,593
-
Total reported value, excl. options
-
$158,538,176
-
Value change
-
+$12,733,385
-
Put/Call ratio
-
7.9%
-
Number of buys
-
34
-
Number of sells
-
-12
-
Price
-
$5.28
Significant Holders of Corvus Pharmaceuticals, Inc. - Common Stock (CRVS) as of Q3 2024
74 filings reported holding CRVS - Corvus Pharmaceuticals, Inc. - Common Stock as of Q3 2024.
Corvus Pharmaceuticals, Inc. - Common Stock (CRVS) has 61 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 30,026,264 shares
of 74,361,296 outstanding shares and own 40% of the company stock.
Largest 10 shareholders include ORBIMED ADVISORS LLC (6,943,654 shares), Point72 Asset Management, L.P. (5,562,729 shares), SAMLYN CAPITAL, LLC (4,530,333 shares), ADAMS STREET PARTNERS LLC (3,275,616 shares), VANGUARD GROUP INC (2,420,619 shares), Vivo Capital, LLC (1,497,268 shares), BlackRock, Inc. (603,877 shares), GEODE CAPITAL MANAGEMENT, LLC (563,009 shares), Ghost Tree Capital, LLC (500,000 shares), and MORGAN STANLEY (393,262 shares).
This table shows the top 61 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.